Particle.news
Download on the App Store

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Roche plans regulatory engagement after ESMO 2025 results showed the clearest gains in ESR1‑mutated tumors.

Overview

  • The evERA trial met co-primary endpoints, reducing the risk of progression or death by 62% in ESR1‑mutated disease and 44% in the overall population.
  • Median progression-free survival reached 9.99 months versus 5.45 months in ESR1‑mutant tumors and 8.77 months versus 5.49 months in the intent‑to‑treat group.
  • The global study enrolled 373 patients post‑CDK4/6 inhibitor therapy and compared an all‑oral giredestrant plus everolimus regimen against standard endocrine therapy plus everolimus in a head‑to‑head design.
  • An exploratory analysis in ESR1‑negative tumors showed no significant PFS advantage, though response rates and duration of response favored the giredestrant combination.
  • Safety was described as manageable, with higher discontinuations on the investigational arm (17% vs 11.8%) and expected adverse events such as stomatitis, diarrhea, and anemia; overall survival remains immature but trends favorable, and Roche will share data with health authorities.